Do we need dosimetry for the optimization of theranostics in CNS tumors?
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noae200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Francesco Cicone und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Radiopharmaceuticals, Radiometry. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: European Union Next-GenerationEU NRRP-Research Projects of National Interest, Italian Ministry for University and Research, European Union Next-GenerationEU NRRP—Research Projects of National Interest.
Abstract (Originalsprache)
Radiopharmaceutical theranostic treatments have grown exponentially worldwide, and internal dosimetry has attracted attention and resources. Despite some similarities with chemotherapy, radiopharmaceutical treatments are essentially radiotherapy treatments, as the release of radiation into tissues is the determinant of the observed clinical effects. Therefore, absorbed dose calculations are key to explaining dose-effect correlations and individualizing radiopharmaceutical treatments. The present article introduces the basic principles of internal dosimetry and provides an overview of available loco-regional and systemic radiopharmaceutical treatments for central nervous system (CNS) tumors. The specific characteristics of dosimetry as applied to these treatments are highlighted, along with their limitations and most relevant results. Dosimetry is performed with higher precision and better reproducibility than in the past, and dosimetric data should be systematically collected, as treatment planning and verification may help exploit the full potential of theranostic of CNS tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
- Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Department of Physics, University of Oslo, Oslo, Norway.
- Department of Diagnostic Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
- Nuclear Medicine Unit, Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
- IRCCS Neuromed, Pozzilli (IS), Italy.
ORCID-Profile: Francesco Cicone
Förderung
- European Union Next-GenerationEU NRRP-Research Projects of National Interest
- Italian Ministry for University and Research
- European Union Next-GenerationEU NRRP—Research Projects of National Interest
Zitieren
APA
Cicone, F., Gnesin, S., Santo, G., Stokke, C., Bartolomei, M., Cascini, G. L., Minniti, G., Paganelli, G., Verger, A., & Cremonesi, M. (2024). Do we need dosimetry for the optimization of theranostics in CNS tumors?. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae200
Vancouver
Cicone F, Gnesin S, Santo G, Stokke C, Bartolomei M, Cascini GL, et al. Do we need dosimetry for the optimization of theranostics in CNS tumors?. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae200
BibTeX
@article{Cicone2024,
author = {Cicone, Francesco and Gnesin, Silvano and Santo, Giulia and Stokke, Caroline and Bartolomei, Mirco and Cascini, Giuseppe Lucio and Minniti, Giuseppe and Paganelli, Giovanni and Verger, Antoine and Cremonesi, Marta},
title = {Do we need dosimetry for the optimization of theranostics in CNS tumors?},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noae200}
}
EUVIMED